Tianchen Biology-B (01779.HK): The Phase III clinical trial of LP-003 for the indication of seasonal allergic rhinitis has reached the primary endpoint.

Wisdom Finance News APP reports that Tianchen Bio-B (01779.HK) has announced that the Phase III clinical trial of LP-003 for seasonal allergic rhinitis has achieved the pre-defined primary endpoint, and these results are highly significant both statistically and clinically.